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Abstract	
Unipolar	 mood	 disorders,	 including	 major	 depressive	 disorder	 and	 persistent	 depressive	
disorder	 (dysthymia),	 confer	 high	 rates	 of	 disability	 and	 mortality	 and	 a	 very	 high	
socioeconomic	burden.	Current	treatment	is	suboptimal	in	most	cases	and	there	is	little	of	
note	in	the	pharmaceutical	development	pipeline.	The	psychedelic	drugs,	including	lysergic	
acid	diethylamide	and	psilocybin,	were	used	extensively	in	the	treatment	of	mood	disorders,	
and	other	psychiatric	conditions,	before	their	prohibition	in	the	late	1960s.	They	are	relatively	
safe	when	used	in	medically	controlled	environments,	with	no	reported	risk	of	dependence.	
Here,	 we	 present	 a	 systematic	 review	 of	 published	 clinical	 treatment	 studies	 using	
psychedelics	 in	 patients	with	 broadly	 defined	 unipolar	mood	 disorder,	 and	 consider	 their	
place	in	psychiatry.	Whilst	all	the	included	studies	have	methodological	shortcomings,	of	423	
individuals	in	19	studies,	335	(79.2%)	showed	clinician-judged	improvement	after	treatment	
with	psychedelics.	A	recently	completed	pilot	study	in	the	UK	favours	the	use	of	psilocybin	
with	psychological	support	in	treatment	resistant	depressive	disorder.	The	evidence	overall	
strongly	suggests	that	psychedelics	should	be	re-examined	in	modern	clinical	trials	for	their	
use	in	unipolar	mood	disorders	and	other	non-psychotic	mental	health	conditions.		
	
Page	2	of	27	
Introduction	
Unipolar	mood	disorders	(UMD),	including	major	depressive	disorder	(MDD)	and	persistent	
depressive	 disorder	 ((PDD),	 previously	 known	 as	 dysthymia),	 are	 common	 psychiatric	
disorders	 associated	 with	 high	 morbidity,	 high	 socio-economic	 burden	 and	 high	 rates	 of	
completed	suicide	(Greenberg	et	al.,	1993;	Harris	and	Barraclough,	1998;	Kessler	et	al.,	2003).	
The	lifetime	prevalence	of	MDD	and	PDD	are	conservatively	estimated	to	be	6.7%	and	3.6%	
respectively	(Waraich	et	al.,	2004)	and	UMD	is	estimated	to	become	the	second	leading	cause	
of	 disability	worldwide	 by	 2020,	 second	 only	 to	 heart	 disease	 (Murray	 and	 Lopez,	 1997).	
UMDs	are	frequently	recurrent.	PDD,	by	definition,	lasts	over	2	years	and	is	often	unremitting.	
Of	those	who	have	had	an	episode	of	MDD	requiring	psychiatric	input,	80%	will	have	another	
(Kessler	et	al.,	2003)	and	the	more	episodes	suffered	the	higher	the	likelihood	of	a	further	
episode	(Keller	et	al.,	1982;	Zis	and	Goodwin,	1979).	In	a	large	study	using	4	successive	medical	
treatment	 steps,	 67%	 of	 patients	 eventually	 achieved	 remission(Rush	 and	 Trivedi,	 2006),	
although	the	remainder,	33%,	did	not.	Those	who	do	not	respond	to	multiple	treatments	have	
a	poor	prognosis	that	contributes	to	a	disproportionate	amount	of	socioeconomic	burden,	
justifying	calls	for	a	research	focus	on	novel	therapeutic	interventions	(Cleare	et	al.,	2015).		
Established	but	controversial	therapies	for	resistant	cases,	such	as	electroconvulsive	therapy	
and	 psychosurgery,	 are	 not	 effective	 in	 all	 cases,	 carry	 substantial	 stigma	 and	 the	 risk	 of	
significant	side	effects	leads	many	patients	to	discount	them	as	potential	treatment	options.	
Many	pharmaceutical	companies	have	ended	research	efforts	into	psychiatric	disorders,	and	
there	are	few	novel	agents	in	development(Hyman,	2013;	Miller,	2010),	leading	some	to	look	
to	history	for	 inspiration.	The	dissociative	drug	ketamine	has	recently	been	investigated	in	
this	 regard,	 however	 whilst	 there	 is	 some	 evidence	 for	 its	 use	 as	 a	 rapidly	 acting	
antidepressant,	the	effects	appear	to	be	transient,	chronic	usage	has	been	associated	with	
urinary	 tract	 problems	 and	 the	 drug	 has	 an	 established	 and	 concerning	 potential	 for	
abuse(Naughton	et	al.,	2014).	
	
Psychedelic	 compounds,	 particularly	 lysergic	 acid	 diethylamide	 (LSD)	 and	psilocybin,	were	
extensively	used	and	researched	in	psychiatry	before	legal	prohibition	in	1967(Grof,	2008).	
The	drugs	were	initially	noted	to	induce	a	temporary	state	of	mind	that	was	not	dissimilar	to	
psychosis.	 Whilst	 this	 suggested	 (and	 more	 formal	 research	 confirmed)	 that	 they	 were	
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probably	not	useful	for	those	with	established	psychotic	disorders,	or	for	those	at	high	risk	of	
developing	 them,	 patients	 suffering	 from	 so-called	 ‘neurotic’	 disorders,	 characterized	 by	
constrained,	entrenched	and	often	negative	patterns	of	thought,	feeling	and	behaviour,	often	
reported	 new	 insights	 under	 the	 influence	 of	 psychedelics	 when	 taken	 in	 therapeutically	
supportive	 settings.	Patients	 sometimes	also	described	 transformative	 states	of	mind	 that	
allegedly	conferred	long-lasting	beneficial	change(Grof,	2008),	and	which	appeared	to	share	
some	similarities	with	the	states	sought	within	the	spiritual,	religious	and	ceremonial	uses	of	
psychedelics,	 for	 which	 evidence	 stretches	 back	 to	 the	 dawn	 of	 recorded	 human	
history(Bruhn	et	al.,	2002;	Ott	and	Bigwood,	1978).		As	well	as	research	in	neuroses,	covered	
in	 this	 review,	an	extensive	 research	program	on	 the	use	of	LSD	 in	 the	psychotherapeutic	
treatment	of	 alcoholism	was	established,	most	notably	 in	Canada(Dyck,	 2006),	 and	 in	 the	
physical	and	existential	pains	experienced	with	terminal	cancer	at	the	Maryland	Psychiatric	
Research	Centre	in	North	America(Grof	and	Halifax,	1977).		The	quality	of	many	studies	was	
suboptimal	by	modern	standards,	with	the	best	quality	research	found	in	alcoholism.	A	recent	
meta-analysis	of	6	good	quality	controlled	trials	of	LSD	treatment	in	alcoholism	found	that	
LSD	treatment	was	 favoured	over	placebo	with	an	odds	ratio	of	1.96	 (95%	CI	1.36	–	2.84,	
p=0.0003)(Krebs	and	Johansen,	2012).		
	
Politically	motivated	and	media	driven	demonization	of	psychedelics	in	the	1960s	and	1970s,	
alongside	 medical	 concern	 for	 the	 occasionally	 harmful	 sequelae	 of	 recreational	 use	 in	
psychologically	 destabilizing	 environments,	 has	 led	 to	 them	 being	 amongst	 the	 most	
stigmatized	and	legally	restricted	of	all	psychoactive	compounds.	However	they	do	not	induce	
dependence(Brunton	 et	 al.,	 2011),	 and	 are	 physiologically(Gable,	 2004)	 and	
psychologically(Cohen,	 1960;	 Strassman,	 1984)	 safe	 when	 used	 in	 medically	 controlled	
settings.	Indeed,	two	separate,	modern	population	studies	have	associated	their	use	with	a	
lower	incidence	of	mental	health	problems	and	no	increased	risk	of	psychosis	(Hendricks	et	
al.,	 2015;	 Johansen	 and	 Krebs,	 2015).	 They	 remain	 classified	 under	 Schedule	 I	 of	 the	 UN	
classification	of	drugs,	severely	restricting	their	use	in	research	and	entirely	preventing	their	
use	in	medical	practice,	a	classification	that	has	been	recently	questioned	(Nutt	et	al.,	2013;	
Rucker,	2015).		
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Since	the	turn	of	the	millennium,	there	has	been	an	upsurge	in	interest	in	the	mechanism	of	
action	 of	 psychedelics	 and	 their	 therapeutic	 utility	 in	 a	 broad	 range	 of	 mental	 health	
problems,	including	UMDs.	Investigations	of	their	pharmacology	(Passie	et	al.,	2002;	2008),	
molecular	 neurobiology(Aghajanian	 and	 Marek,	 1999;	 Halberstadt	 and	 Geyer,	 2011;	 JL	
Moreno	et	al.,	2011;	Vollenweider	and	Kometer,	2010),	neuroimaging	correlates	 (Carhart-
Harris	 et	 al.,	 2012;	 Carhart-Harris,	 Muthukumaraswamy,	 et	 al.,	 2016)	 and	 therapeutic	
mechanisms(Bogenschutz	and	Pommy,	2012;	 Loizaga-Velder	and	Verres,	2014;	Maji	et	al.,	
2015;	 Tupper	 et	 al.,	 2015)	 have	 been	 published.	 The	 reviews	 of	 Nichols	 are	 particularly	
comprehensive	(Nichols,	2004;	2016).	Safety	guidelines	for	the	use	of	psychedelics	in	modern	
clinical	research	settings	are	also	available(M	Johnson	et	al.,	2008)	and	pilot	clinical	studies	in	
anxiety	associated	with	advanced	cancer(Gasser	et	al.,	2015;	Grob	et	al.,	2011),	obsessive	
compulsive	 disorder(FA	 Moreno	 et	 al.,	 2006),	 tobacco(MW	 Johnson	 et	 al.,	 2014)	 and	
alcohol(Bogenschutz	et	al.,	2015)	addiction	and	cluster	headaches(Sewell	et	al.,	2006)	have	
been	completed	over	the	last	10	years,	with	encouraging	results.	Some	have	also	argued	that	
psychedelics	 may	 confer	 new	 insights	 into	 the	 nature	 of	 psychotic	 disorders	 such	 as	
schizophrenia(González-Maeso	 and	 Sealfon,	 2009)	 and	 wider	 theories	 of	 brain	
function(Carhart-Harris	and	Friston,	2010).			
	
In	this	paper,	we	systematically	collated	the	pre-prohibition	literature	on	the	therapeutic	use	
of	 psychedelics	 on	 broadly	 defined	 unipolar	 mood	 disorder,	 within	 which	 we	 include	
contemporary	 depressive	 disorder	 with	 co-morbid	 anxiety,	 as	 well	 as	 disorders	 grouped	
under	the	old-fashioned	terms	‘neurotic’	and	‘psychoneurotic’	disorders.	This	is	with	the	aim	
of	 evidencing	 the	debate	on	whether	 these	 substances	 should	be	 reinvestigated	with	 the	
benefit	of	modern,	more	systematic	trial	methodology.	Pre-prohibition	literature	is	described	
and	 synthesised	and	 this	 is	used	 to	 inform	a	discussion	on	 the	benefits	 and	challenges	of	
integrating	contemporary	psychedelic	research	into	modern	clinical	trial	designs.	 	
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Methods	
 
The	PsycINFO	and	MEDLINE	databases	(1940-2000)	were	searched	using	the	following	terms:	
LSD,	 lysergic	acid	diethylamide,	psychedelic	or	hallucinogen	and	therapy,	psychotherapy	or	
treatment.	 The	 ‘Multidisciplinary	 Association	 for	 Psychedelic	 Studies’	 (MAPS)	 Psychedelic	
Bibliography	 contains	 a	 comprehensive	 overview	 of	 psychedelic	 research,	 including	 a	
complete	 list	of	 all	 studies	on	 the	 therapeutic	use	of	psychedelics	 from	1931-1995(MAPS,	
2016).	This	database	was	also	manually	searched	to	find	titles	or	abstracts	including	the	above	
search	terms.	
Search	 results	were	screened	by	 reading	 the	 titles	and	abstracts.	More	detailed	 review	of	
each	potentially	relevant	paper	 identified	clinical	studies	referring	to	the	use	of	LSD	in	the	
treatment	of	‘Depressive’,	‘Neurotic’	and	‘Psychoneurotic’	patients.	Subsequent	examination	
of	reference	lists	identified	other	potential	eligible	studies	or	review	articles.	Where	studies	
referred	 to	 the	 treatment	 of	multiple	 patient	 populations,	 results	 of	 treatment	 for	 these	
selected	groups	were	extracted.	The	findings	are	summarized	in	Table	1.	
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Author	 Year	 Sample	
size	(n)	
Population	 Dose	range	 Frequency	of		
sessions	
Number	 of	
sessions	
Percentage	
improvement	(n)	
Condrau	 1949	 5	 ‘Depressives’	 ‘Daily	increasing’	 Daily	 Several	 40%	(2)	
Busch	and	Johnson	 1950	 5	 ‘Psychoneuroses’	 30-40mcg	 Unknown	 Unknown	 40%	(2)	
Savage	 1952	 15	 ‘Depressives’	 20-100mcg	 Daily	 Up	to	30	 47%	(7)	
Sandison*	 1954	 30	 ‘Neurotics’	and	‘Depressives’	 25-400mcg	 Weekly	 2	–	40	 90%	(27)	
Sloane	 1954	 12	 ‘Depression’	 40-120mcg	 Once	 1	 Unclear	
Langner	and	Kemp	 1956	 19	 ‘Psychoneuroses’	 Unknown	 Unknown	 Unknown	 58%	(11)	
Martin	 1957	 22	 ‘Psychoneuroses’	 40-160mcg	 Weekly	 2	–	13		 91%	(20)	
Sandison*	 1957	 35	 ‘Psychoneurotic	depression’		
and	‘Primary	anxiety	neurosis’	
50-200mcg	 Weekly	 Up	to	30	 71%	(25)	
Lewis	and	Sloane	 1958	 11	 ‘Psychoneuroses’	 25-500mcg	 Biweekly-	weekly	 1	–	25	 64%	(7)	
Eisner	and	Cohen	 1958	 5	 ‘Depressive	reactions’	 25-100mcg	 Weekly	 2	–	6	 80%	(4)	
Chandler	and	Hartman	 1960	 44	 ‘Psychoneuroses’	 25-150mcg	 1-	6	weeks		 1	–	26	 Unclear	
Maclean	 1961	 25	 ‘Anxiety’	and		
‘Depressive	reaction	neuroses’	
400-1500mcg	 Once	 1	 92%	(23)	
Sherwood	
	
1962	 7	 ‘Neuroses’	 100-200mcg	LSD	and	
200-400mg	Mescaline	
Once	 1	 57%	(4)	
Martin	 1964	 60	 ‘Severe	neurotics’	 Unknown	 Weekly	 Mean	=	20	 95%	(57)	
Geert-Jörgensen	 1964	 28	
	
‘Anxiety	 neuroses’,	 ‘Depressive	 neuroses’	 and	
‘Endogenous	depression’	
50-400mcg		 Unknown	 5	–	58	 68%	(19)	
Whitaker	 1964	 21	 ‘Depression’	 100-250mcg	 Unknown	 Mean	=	3.28	 81%	(17)	
Savage	
	
1966	 77	 ‘Neurotics’	and	‘Depressives’	 200-300mcg	LSD		
±	200-300mg	Mescaline	
Once	 1	 80%	(62)	
Savage	 1967	 36	 ‘Psychoneurotic	depressive	reaction’	 200-300mcg	LSD		
±	200-400mg	Mescaline	
Once	 1	 81%	(29)	
Baker	 1967	 11	 ‘Depressives’	 100-2000mcg	 Weekly	 1	–	10	 91%	(10)	
Leuner	 1967	 11	 ‘Depressive	reactions’	 30-200mcg	 Biweekly-	weekly	 2	to	16	 82%	(9)	
Savage	 1973	 63	 ‘Severe	chronic	neuroses’	 50mcg	or	350mcg	 Once	 1	 Unclear	
Table	1:	Summary	of	studies	included	in	the	systematic	review.		*	indicates	overlapping	populations	in	the	studies	of	Sandison	1954	and	1957			
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Description	of	Studies 
In	 the	 first	 report	on	 the	 therapeutic	use	of	 LSD	 in	1949,	Condrau	proposed	 its	use	as	an	
antidepressant	based	on	the	euphoric	properties	of	the	drug	(Condrau,	1949).	Through	the	
administration	of	 small	 and	progressively	 increasing	daily	doses	he	explains	 that	although	
some	depressed	patients	showed	some	improvement	in	mood	following	LSD	treatment,	the	
results	were	not	convincing	and	he	felt	 the	observed	changes	did	not	exceed	the	 limits	of	
spontaneous	variation.	A	similar	study	by	Savage	et	al.,	using	daily	doses	of	20-100mcg	of	LSD	
in	 15	 patients	 with	 depressive	 reactions,	 reported	 that	 3	 recovered	 fully	 and	 4	 others	
improved	after	1	month	of	treatment(Savage,	1952).	
The	 first	 group	 to	 use	 LSD	 as	 an	 adjunct	 to	 traditional	 psychotherapy	 were	 Busch	 and	
Johnson(Busch	and	WC	Johnson,	1950).	During	LSD	therapy,	5	psychoneurotic	patients	all	had	
experiences	which	the	authors	felt	profoundly	influenced	the	course	of	their	illness,	with	2	of	
the	patients	improving	sufficiently	to	discontinue	treatment.	However,	there	is	no	indication	
in	the	paper	as	to	the	frequency	and	number	of	sessions	or	the	specific	techniques	used.		
The	approach	of	periodic	low	dose	use	of	LSD	combined	with	psychotherapy	later	came	to	be	
known	as	the	 ‘psycholytic’	approach.	This	method	was	pursued	by	Sandison	et	al.	who,	 in	
1954,	published	 the	 results	of	 treatment	 in	36	patients	with	psychoneuroses	 in	a	hospital	
setting(Sandison	et	al.,	1954).	Treatments	occurred	at	weekly	intervals.	For	the	scope	of	this	
review,	 6	 patients	 were	 excluded:	 4	 conversion	 hysteria,	 1	 homosexuality,	 1	 schizoid	
personality.	Researchers	started	LSD	treatment	at	25mcg	and	gradually	increased	the	dose	in	
subsequent	 sessions	until	 an	 “adequate	 reaction”	was	obtained.	 Treatment	was	 repeated	
once	a	week	and	after	two	to	four	weeks	the	team	decided	whether	sessions	continued	in	
the	outpatient	setting	or	whether	the	patient	remained	in	hospital.	Out	of	the	30	patients	
included	 in	 this	 review	the	authors	 report	 that	12	 recovered	and	15	others	 showed	some	
degree	of	improvement.	
This	team	published	a	subsequent	paper	3	years	later	with	further	results	from	a	total	of	100	
patients	that	had	been	treated	to	date(Sandison	and	Whitelaw,	1957).	 Improvement	 in	25	
out	of	35	patients	described	as	suffering	from	‘psychoneurotic	depression’	or	‘primary	anxiety	
neuroses’	was	seen.	Unfortunately,	it	was	impossible	to	differentiate	the	findings	for	patients	
in	the	first	study	from	the	cumulative	total	so	there	will	be	a	degree	of	overlap	in	the	reported	
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data	from	these	2	papers	in	Table	1.		The	authors	conclude	that	LSD	appears	to	be	of,	“utmost	
value	in	psychotherapy,	both	in	cases	otherwise	resistant	to	treatment	and	as	a	method	of	
avoiding	 the	 prolonged	 time	 necessary	 for	 a	 full	 psychological	 analysis.”(Sandison	 and	
Whitelaw,	1957)	
In	an	attempt	to	obtain	objective	estimates	of	some	of	the	physiological	and	psychological	
changes	produced,	Sloane	et	al.	administered	LSD	to	11	healthy	controls,	12	patients	with	
predominant	 depression	 and	 7	 patients	 with	 schizophrenia	 at	 doses	 between	 40mcg-
120mcg(B	 Sloane	and	 Lovett	Doust,	 1954).	Although	3	of	 the	depressive	patients	 showed	
some	 lightening	 of	 their	 mood,	 the	 authors	 conclude,	 “it	 proved	 difficult	 to	 obtain	 valid	
differentiating	measures	of	clinically	apparent	changes.”		
Langner	 and	 Kemp	 give	 a	 brief	 report	 on	 their	 results	 of	 	 over	 500	 LSD	 	 psychoanalytic	
treatment	sessions	in	40	patients	(Langner	and	Kemp,	1956).	Although	no	specific	technique	
or	dosing	is	described,	they	claim	that	in	a	group	of	‘psychoneurotics,’	recovery	or	marked	
improvement	was	seen	in	11	out	of	19	patients.	
Assessing	the	potential	use	and	feasibility	of	LSD	in	the	treatment	of	chronic	psychoneurotic	
disorders	under	day-patient	conditions,	Martin	describes	further	promising	results	(Martin,	
1957).	Patients	arriving	at	the	unit	in	the	morning	were	given	an	initial	dose	of	25-50mcg	that	
increased	slightly	with	each	treatment	until	an	optimal	reaction	was	obtained.	The	sessions	
were	terminated	by	giving	50mg	chlorpromazine,	6	hours	after	the	initial	LSD	dose	and	the	
patient	was	then	permitted	to	travel	home	accompanied	by	a	friend	or	relative	by	the	end	of	
the	day.	The	authors	note	that	some	patients	became	more	readily	“accessible”	under	LSD	
and	suggest	that	its	therapeutic	effect	is	in	part	due	to	the	reliving	of	early	experiences	and	
release	of	repressed	feelings.	Although	the	study	describes	the	treatment	of	50	patients	with	
chronic	psychoneurosis	this	review	excluded	28	patients	described	as	‘psychopaths’,	‘sexual	
neurotics’	 and	 ‘obsessional’.	 Those	 remaining	 were	 described	 as	 suffering	 from	 ‘chronic	
tension	states’	and,	in	this	group	of	22	patients,	although	only	1	had	fully	recovered,	19	others	
showed	significant	improvement.	
Working	with	a	group	of	23	psychiatric	inpatients,	Lewis	and	Sloane	report	results	no	better	
than	those	obtained	with	other	treatments(Lewis	and	RB	Sloane,	1958).	However,	excluding	
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those	 with	 schizophrenia	 and	 ‘obsessional	 illness’	 gives	 more	 favourable	 results	 in	 the	
remaining	11	patients	with	 ‘psychoneuroses’,	 in	which	a	 total	 of	 7	 showed	 improvement.	
Again	the	authors	concluded	that,	“the	drug	provided	a	useful	aid	to	the	psychotherapeutic	
technique”(Lewis	 and	RB	 Sloane,	 1958).	 In	 another	 study	 from	 the	 same	year,	 Eisner	 and	
Cohen	administered	LSD	to	22	patients	weekly	for	an	average	of	five	to	six	weeks(Eisner	and	
Cohen,	 1958).	 The	 authors	 suggest	 that	 those	 with	 depressive	 states	 appear	 to	 be	 very	
suitable	for	treatment,	with	improvement	seen	in	80%	of	patients	(4	out	of	5)	suffering	from	
‘depressive	reactions’	after	a	follow	up	period	of	6	to	18	months.	
Further	 investigating	the	use	of	LSD	as	a	facilitating	agent	 in	psychotherapy,	Chandler	and	
Hartman	 report	 on	 their	 work	 in	 110	 patients	 in	 whom	 LSD	was	 utilised	 as	 part	 of	 their	
treatment(Chandler	and	Hartman,	1960).	The	patient	population	included	‘psychoneuroses’,	
‘personality	disorders’	and	‘addictions.’	Some	of	these	had	already	received	psychoanalytic	
treatment	 for	up	to	6	years	previously	without	significant	 improvement.	Patients	 received	
LSD	at	doses	increasing	gradually	from	25-150mcg,	from	1-26	times,	at	intervals	of	1-6	weeks.	
The	authors	report	an	improvement	in	80%	of	patients	and	that	in	only	3	cases	did	LSD	fail	to	
facilitate	 psychotherapy.	 Unfortunately,	 the	 exact	 proportion	 of	 the	 44	 patients	 with	
‘psychoneuroses’	that	contribute	to	this	total	percentage	remains	unclear	from	the	paper.	
The	authors	claim	nonetheless	that	the	majority	of	patients	in	this	subgroup	showed	some	
improvement.	The	authors	conclude	that	compared	with	previous	therapy	without	any	drugs,	
“With	LSD	therapy	most	patients	showed	greater	depth	of	therapy	and	greater	acceleration	
of	therapy,”	and	that,	“patients	who	would	be	unacceptable	for	analysis	or	almost	any	type	
of	deep	psychotherapy	were	benefited	by	LSD	therapy.”(Chandler	and	Hartman,	1960)	
A	very	different	therapeutic	method	is	described	by	Maclean	et	al.	in	the	treatment	of	100	
patients	 (61	 alcoholics	 with	 poor	 prognosis	 and	 39	 patients	 with	 other	 psychiatric	
disorders)(Maclean	 et	 al.,	 1961).	 Instead	 of	 using	 the	 ‘psycholytic’	 approach	 of	 repetitive	
lower	doses	of	the	drug,	considerably	larger	doses	of	LSD	ranging	from	400-1500mcg	were	
administered	 in	 a	 one	 off	 session.	 This	 is	 known	 as	 the	 ‘psychedelic’	 approach.	 A	 group	
technique	was	 also	 used	 and	 generally	 a	 psychiatrist,	 psychologist,	 psychiatric	 nurse	 and	
music	therapist	were	present	for	each	therapy	session.	Utilising	this	method,	in	a	group	of	25	
patients	 suffering	 from	 ‘anxiety’	 and	 ‘depressive	 reaction	 neuroses’,	 improvement	 was	
reported	in	92%	of	patients.	
Page	10	of	27	
Sherwood	et	al.	describe	the	‘psychedelic’	approach	further	where,	“an	individual	can	have	a	
single	experience	which	is	so	profound	and	impressive	that	his	life	experience	in	the	months	
and	 years	 that	 follow	 become	 a	 continuing	 growth	 process.”(Sherwood	 et	 al.,	 1962)	 The	
authors	 report	 on	 25	 cases	 (marital	 problems,	 alcoholism,	 personality	 disorders	 and	
neuroses)	 in	 which	 simultaneous	 doses	 of	 LSD	 and	 mescaline	 were	 administered	 in	 an	
attempt	to	produce	such	unique	experiences.	Improvement	was	seen	in	84%	of	the	total	cases	
but	 specifically	 4	 out	 of	 7	 (57%)	 in	 the	 ‘neuroses’	 group.	 It	 was	 felt	 the	 amount	 of	
improvement	is	correlated	with	the	subject’s	willingness	to	face	himself	during	the	session,	
accept	the	material	encountered	and	act	upon	it.	
Another	method	of	LSD	treatment	in	neurotic	disorders	is	described	by	Martin	in	which	the	
therapist	takes	a	more	direct	approach	with	the	patient,	sitting	with	them	through	most	of	
the	 session,	 playing	 a	 different	 role	 for	 each	 patient	 according	 to	 their	 emotional	
needs(Martin,	 1964).	 The	 authors	 report	 impressive	 results	 with	 their	 technique	 that	
combines	both	behaviouristic	and	psychoanalytic	methods	of	therapy.	Response	was	seen	in	
95%	(57	out	of	60)	of	patients	described	as	‘severe	neurotics’	receiving	LSD	analysis	weekly	
for	an	average	of	20	sessions.	No	information	is	provided	as	to	the	doses	involved.	
Further	work	on	the	use	of	LSD	in	the	treatment	of	‘chronic	neurotics’	is	described	by	Geert-
Jörgensen	 et	 al.(Geert-Jörgensen	 et	 al.,	 1964).	 In	 a	 group	 of	 129	 patients	 who	 had	 not	
benefited	 from	 years	 of	 therapy	 before	 being	 treated	 with	 LSD	 they	 report	 a	 total	
improvement	 rate	 of	 55%.	 For	 the	 purpose	 of	 this	 review,	 including	 only	 those	 patients	
described	 as	 ‘anxiety	 neuroses’,	 ‘depressive	 neuroses’	 or	 ‘endogenous	 depression’	 the	
percentage	improvement	increases	to	68%	(19	out	of	28).		
A	 shared	 theme	 throughout	 the	 studies	described	 so	 far	 is	 the	 lack	of	 any	 control	 group.	
Whitaker,	an	Australian	psychiatrist,	describes	his	findings	in	the	use	of	LSD	in	psychotherapy	
in	 100	 patients(Whitaker,	 1964).	 He	 explains	 the	 method	 of	 setting	 up	 a	 control	 group	
presented	serious	difficulty	as,	“The	response	of	the	first	few	patients	was	so	encouraging	
that	 it	 was	 considered	 that	 it	 would	 be	 unfair	 to	 withhold	 LSD	 from	 apparently	 suitable	
patients	in	the	interests	of	experimental	design.”	Instead	a	control	group	was	selected	from	
patients	treated	in	recent	years	of	a	similar	range	of	diagnoses	and	duration	of	illness.	In	the	
LSD	 group	 47%	 of	 cases	 were	 successful,	 18%	were	 borderline	 successful	 and	 35%	were	
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failures.	This	compares	with	the	retrospectively	collected	control	group	in	which	only	12%	of	
cases	were	successful,	30%	were	borderline	successful	and	58%	were	failures	(Pearson’s	chi2	
test	for	significant	differences	between	the	control	and	LSD	groups:	p	=	4.03x10-7).	Focusing	
on	those	with	‘depression,’	treated	with	LSD	psychotherapy,	an	improvement	was	reported	
in	17	out	of	21	patients	(81%).	
Other	groups	have	found	similarly	effective	results	using	LSD	in	the	treatment	of	depressive	
patient	groups.	Baker	describes	results	 in	the	treatment	of	150	psychiatric	patients	over	a	
four	year	period	from	1961-1964(Baker,	1967).	Improvement	was	seen	in	91%	of	‘depressive’	
cases	(10	out	of	11).	Comparable	results	are	described	in	a	report	by	Leuner	in	another	group	
of	11	patients	with	‘depressive	reactions,’	in	which	improvement	was	seen	in	8	patients	(73%)	
following	LSD	psychotherapy(Leuner,	1967).	
The	largest,	most	sustained	and	systematic	studies	of	psychedelic	drugs	and	psychotherapy	
to	date	were	 carried	out	at	 the	Spring	Grove	State	Hospital	 and	 the	Maryland	Psychiatric	
Research	Center	 through	 the	1960s	 and	early	 1970s.	 Savage	et	 al.	 report	 on	work	with	 a	
cohort	 of	 ‘neurotics’	 and	 ‘depressives’	 treated	 in	 an	 outpatient	 setting(Savage,	 Fadiman,	
Mogar	 and	 Allen,	 1966a).	 Following	 a	 period	 of	 extensive	 preparation	 involving	 weekly	
interviews	for	four	to	eight	weeks,	patients	would	undergo	a	single	high-dose	‘psychedelic’	
session.	 Patients	 were	 given	 200-300mcg	 of	 LSD	 together	 with	 200-300mg	Mescaline	 “if	
necessary”,	 spending	 the	day	 in	 the	company	of	a	male	and	 female	 therapist,	 listening	 to	
music	or	viewing	visual	stimuli	such	as	family	photographs.	 Instead	of	providing	any	direct	
interpretation,	 the	 therapists’	 role	 during	 the	 session	 was	 one	 of	 companionship	 and	
emotional	 support.	 This	 focus	on	 a	 supportive	 rather	 than	 an	 active	 therapeutic	 role	was	
based	on	the	shared	expectation	between	patient	and	therapist	that	the	patient	would	have	
their	 own	 experience	 in	which	 they	would	 learn	 something	 about	 themselves	 that	might	
prove	useful	in	altering	their	life	in	a	more	self-fulfilling	direction.		Regular	interviews	in	the	
period	 following	 the	 session	 provided	 the	 opportunity	 for	 analysis	 and	 integration	 of	 the	
patient’s	experience.	The	authors	 report	 improvement	 in	80%	 (62	out	of	77)	 following	an	
evaluation	at	6	months.	Later	this	team	provided	an	analysis	of	a	larger	group	of	243	patients	
that	had	been	through	the	same	program(Savage	et	al.,	1967).	Consistent	improvement	was	
seen	in	81%	of	the	total	cohort	(197	out	of	243)	and	more	specifically	in	81%	of	patients	with	
‘psychoneurotic	depressive	reactions’	(29	out	of	36).		
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The	 final	 study	 included	 in	 this	 review	was	 carried	out	at	 the	Spring	Grove	State	Hospital	
investigating	LSD-assisted	psychotherapy	in	the	treatment	of	inpatients	with	‘severe	chronic	
neuroses’(Savage	 et	 al.,	 1973).	 After	 an	 initial	 psychiatric	 assessment,	 96	 patients	 were	
randomly	assigned	to	a	high	dose	(350mcg)	LSD	group,	a	low	dose	(50mcg)	LSD	control	group	
and	 a	 conventional	 treatment	 group.	 Personality	 and	 behaviour	 measures	 (Minnesota	
Multiphasic	 Personality	 Inventory	 (MMPI),	 the	 Eysenck	 Personality	 Inventory,	 and	 the	
Personal	 Orientation	 Inventory)	 were	 administered	 before	 and	 5-7	 days	 after	 treatment.	
Significant	treatment	effects	occurred	in	19	out	of	50	test	variables	indicating	superiority	of	
high	 dose	 LSD	 treatment	 over	 conventional	 treatment.	 Although	 usually	 of	 a	 lower	
magnitude,	low	dose	LSD	treatment	was	also	found	to	be	superior	to	conventional	treatment	
with	significant	treatment	effects	in	11	of	the	50	test	variables.		
Discussion	
We	have	collated	and	summarized	the	pre-prohibition	literature	on	the	use	of	psychedelics	
in	the	treatment	of	broadly	defined	UMD	in	Table	1.	22	studies	published	between	1949	and	
1973	were	included.	LSD	was,	by	far,	the	most	commonly	used	psychedelic.	Mescaline	was	
occasionally	used.	The	absence	of	psilocybin	is	discussed	below.	The	sample	size	ranged	from	
5	to	77,	with	a	total	aggregated	sample	size	of	423	across	all	the	studies	where	this	was	clearly	
defined.	 The	 number	 of	 psychedelic	 sessions	 ranged	 from	 1	 to	 58	 and	 the	 therapeutic	
paradigms	applied	were	variable.	The	dose	of	LSD	used	ranged	from	20	micrograms	to	1,500	
micrograms.	Mescaline	was	 used	 at	 doses	 of	 200-400mg,	 in	 combination	with	 LSD.	Many	
studies	used	titrated	dosing	schedules	that	took	account	of	individual	patient	responses	to	
the	drug.		
	
Savage(Savage,	 Fadiman,	 Mogar	 and	 Allen,	 1966b),	 in	 1966,	 neatly	 summarized	 the	
methodological	difficulties	of	these	pre-prohibition	papers.	
	
“Nearly	 all	 studies	 have	 serious	 shortcomings…namely,	 1)	 anecdotal	 evidence;	 2)	
inadequate	 assessment	 procedures;	 3)	 insufficient	 follow	 up;	 4)	 naïve	 statistical	
treatment;	5)	lack	of	controls.”	
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We	agree	with	these	criticisms,	noting	also	that	a	meta-analytical	approach	to	the	reported	
studies	 is	 impossible	 as	 continuous	 outcome	measures	were	only	 collected	by	 1	 research	
group.	Only	4	studies	have	any	mention	of	a	control	group(Savage,	1952;	Savage	et	al.,	1973;	
B	Sloane	and	Lovett	Doust,	1954;	Whitaker,	1964)	and	in	only	one(Savage	et	al.,	1973)	could	
the	 control	 group	 be	 deemed	 to	 be	A)	 adequately	 selected	 and	B)	 adequately	 described.		
Outcomes	 measures	 were	 generally	 so	 vague	 that	 the	 only	 meaningful	 grouping	 was	 a	
dichotomous	variable	reflecting	those	who	were	felt	by	their	clinicians	to	have	‘improved’,	as	
opposed	to	those	that	didn’t.	Given	the	heterogeneity	in	definition,	‘improvement’	cannot	be	
further	defined.	Clearly	this	is	subject	to	bias	and	is	neither	systematic	nor	objective.	In	those	
studies	where	 the	 number	 of	 patients	who	were	 deemed	 to	 have	 improved	was	 actually	
specified	 (19	 out	 of	 22),	 335	 (79.2%)	 out	 of	 423	 patients	were	 judged	 to	 have	 improved,	
ranging	in	the	various	studies	from	40%	to	95%.	Studies	using	higher	doses	of	psychedelics	
and/or	combining	psychedelics	with	psychotherapy	or	psychological	support	appear	to	show	
better	results.	
	
In	 an	 attempt	 to	 delineate	 more	 classical	 depressive	 disorders	 from	 the	 wider	 clinical	
definitions	 of	 ‘anxiety’	 and	 ‘neurotic’	 disorders	 subsumed	 within	 our	 analysis,	 we	 also	
repeated	 this	analysis	 restricted	 to	cases	classified	as	 ‘depressives,’	 ‘depressive	 reactions,’	
and	‘depressive	neuroses’,	where	this	was	specified.	Of	the	papers	where	there	was	sufficient	
information	 to	 do	 this	 (11	 out	 of	 a	 total	 of	 21	 papers)	 improvement	 was	 seen	 in	 73.7%	
(101/137).	Further	restricting	the	sample	to	purely	‘depressives’	and	‘depressive	reactions’,	
improvement	was	seen	in	72.5%	(58/80).	Data	on	those	who	were	felt	to	have	worsened	with	
treatment	 was	 either	 incomplete,	 or	 not	 included	 at	 all.	 The	 degree	 of	 improvement	 is	
notable	even	if	the	presumption	must	be	that	it	is	biased	in	favour	of	a	therapeutic	effect.	
The	research	deserves	repetition	in	a	modern,	controlled	context.	
	
In	response	to	the	Thalidomide	tragedy,	the	US	introduced	the	Kefauver-Harris	Drug	Efficacy	
Amendments	in	1962,	which	required	well	controlled	trials	to	evidence	a	drug’s	efficacy	and	
safety	 before	 it	 could	 be	 marketed(Peltzman,	 1973).	 These	 changes	 heralded	 modern	
paradigms	of	trial	design,	which	rely	on	randomisation	of	individuals	to	a	placebo	or	active	
treatment,	and	blinding	of	both	assessor	and	participants	to	the	intervention.	This	is	thought	
to	partially	compensate	for	selection,	performance	and	detection	bias	and	serves	to	isolate	
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the	effect	of	the	drug	from	the	confounds	of	its	surroundings.	However,	there	are	inherent	
difficulties	with	such	designs	when	psychotropic	drugs	are	being	used,	and	particularly	with	
psychedelics(Oram,	2012),	for	four	reasons.		
	
Firstly,	blinding	is	largely	impossible.	Therapeutic	doses	of	psychedelics	induce	subjective	and	
objective	changes	in	feeling,	thinking	and	behaviour	that	are	usually	obvious	both	to	recipient	
and	observer.	Secondly,	and	on	this	basis,	placebo	control	is	problematic	because	the	absence	
of	the	psychedelic	effect	is	also	obvious.	Thirdly,	and	perhaps	most	pertinently	to	psychedelic	
trials,	 the	 ‘set’	 (psychological	state)	and	 ‘setting’	 (interpersonal	and	physical	environment)	
within	 which	 the	 drug	 is	 experienced	 are	 inextricably	 linked	 to	 the	 therapeutic	
effect(Grinspoon	and	Bakalar,	1997).	Attempting	to	isolate	the	drug	from	these	variables,	as	
modern	trials	attempt	to	do,	will	miss	the	widely	accepted	point	that	the	therapeutic	effect	
is	 subsumed	 within,	 and	 inextricable	 from,	 the	 interaction	 between	 psychedelic,	 set	 and	
setting.	Finally,	and	a	point	common	to	trials	in	mood	disorders	in	general,	the	diagnostic	and	
aetiological	heterogeneity	in	patients	diagnosed	with	UMD	is	famously	wide.	Some	patients	
have	broadly	adaptive	personalities	with	particular	sensitivities	to	certain	stressors.	Others	
have	 chronic	 and	 enduring	 patterns	 of	 learned	 helplessness	 or	 other	 personality	 factors.	
Others	may	have	biologically	mediated	mood	problems	derived	from	subclinical	imbalances	
in	 immune	 or	 endocrine	 function.	 Most	 will	 have	 a	 variable	 mixture	 of	 these	 factors	
contributing	to	the	clinical	picture.	Consequently,	routine	clinical	treatments	for	UMDs	are	
also	 variable,	 requiring	 a	 flexibility	 in	 clinical	 approach	 that	 modern	 trial	 designs	 are	
particularly	designed	to	avoid.	
	
Active	placebos	have	been	used	 to	 attempt	 to	 compensate	 for	difficulties	 in	blinding	 and	
placebo	 control.	 In	 a	 randomized,	 double	 blind	 trial	 using	 psilocybin	 in	 psychedelic-naïve	
volunteers	over	two	or	three	sessions	to	investigate	mystical	experiences,	clinicians	were	told	
that	participants	would	receive	at	least	one	dose	of	psilocybin,	but	that	at	other	sessions	a	
variety	of	other	drugs	might	be	administered(Griffiths	et	al.,	2006).	They	were	then	asked	to	
guess	 the	 drugs	 used	 immediately	 after	 each	 session.	 In	 fact,	 only	 psilocybin	 or	
methylphenidate	 were	 used	 in	 the	 trial.	 23%	 of	 sessions	 were	 misclassified	 (that	 is,	 the	
clinician	 either	 thought	 a	 methylphenidate	 session	 was	 a	 psilocybin	 session	 or	 that	 a	
psilocybin	 session	 was	 something	 other	 than	 psilocybin).	 However	 when	 clinicians	 did	
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misclassify	a	 session	 they	 tended	 to	misclassify	a	methylphenidate	 session	as	a	psilocybin	
session.	Furthermore,	when	psilocybin	was	given	but	the	clinician	did	not	accurately	guess	
this,	most	participants	still	reported	deeply	meaningful,	mystical	experiences.	This	suggests	
that	 the	 occurrence	 of	 a	 mystical	 experience	 is	 not	 likely	 to	 be	 an	 artefact	 simply	 of	
expectation	or	suggestion(Griffiths	et	al.,	2006),	and	may	suggest	that	the	double	blind,	active	
placebo	condition	 is	a	more	 favourable	 trial	design.	Randomisation	between	 low	and	high	
doses	of	psychedelic	is	also	a	credible	design	strategy	given	the	difficulties	described,	a	design	
that	 was	 partially	 implemented	 in	 a	 study	 in	 1973	 by	 Savage	 et	 al.	 included	 in	 this	
review(Savage	et	al.,	1973).	This	showed	statistically	significant	superiority	of	LSD	at	a	dose	
of	 350	 micrograms	 when	 compared	 to	 conventional	 treatment	 over	 a	 wide	 range	 of	
psychological	 test	 variables	 in	 a	 sample	 of	 96	 patients	 with	 ‘severe	 chronic	 neuroses’	
randomized	to	low	dose	LSD,	high	dose	LSD	and	treatment	as	usual.	Correction	for	multiple	
statistical	comparisons	was	not	performed.		
	
Attempts	to	standardize	the	context,	or	setting,	of	the	psychedelic	experience	are	possible	in	
controlled	trials,	but	the	number	of	variables	implied	by	this	and	the	pragmatics	of	controlling	
them,	suggests	that	a	significant	degree	of	variation	is	unavoidable.	Whilst	the	dose	of	drug	
and	basic	environmental	context	(the	layout	of	the	room,	decoration,	sound	and	ambience,	
for	example)	can	be	largely	controlled	in	medical	research	settings,	the	psychotherapy	itself	
must	 inevitably	 be	 flexible.	 Defined	 training	 programs	 in	 psychedelic	 research	 and	
psychotherapy	 are	now	being	 set	 up	 to	provide	 some	 structure	 for	 this,	 such	 as	 the	new	
‘Certificate	in	Psychedelic-Assisted	Psychotherapies	&	Research’	in	California,	which	took	its	
inaugural	intake	of	students	in	2015(Denenmark,	2015).	However,	a	raft	of	questions	remain	
to	be	answered.	In	the	pre-prohibition	literature,	distinction	was	made	between	‘psycholytic’	
therapy,	which	used	low	doses	of	psychedelics	to	facilitate	access	to	unconscious	material,	
and	 ‘psychedelic’	 therapy,	 which	 used	 high	 doses	 to	 elicit	 therapeutic	 mystical/spiritual	
experiences.	There	is	some	evidence	that	mystical	experiences	with	psilocybin	are	associated	
with	 increased	 well-being	 and	 personal	 meaning	 over	 a	 year	 later(Griffiths	 et	 al.,	 2008),	
however	it	is	not	known	whether	one	paradigm	is	generally	superior	to	the	other,	or	whether	
there	is	variation	in	response	according	to	disorder	and	paradigm	used.		
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Carefully	 designed	 clinical	 trials	 that	 incorporate	 biological	 mechanism	 studies	 may	 help	
resolve	some	questions.	For	example,	the	dichotomy	between	the	more	verbal	‘psycholytic’	
paradigm	and	the	largely	ineffable	‘psychedelic’	paradigm	raises	the	question	of	whether	they	
reflect	a	common	continuum	of	response	to	psychedelics,	or	distinct	entities	in	themselves.	
Modern	neurobiology	and	neuroimaging	studies	may	help	answer	this	question,	and	ideally	
such	appraisals	of	mechanism	will	need	to	be	embedded	within	clinical	efficacy	trials.	If	the	
two	paradigms	appear	mechanistically	distinct	in	terms	of	neurobiology,	it	may	suggest	that	
the	 two	 paradigms	 will	 have	 different	 therapeutic	 efficacies	 in	 different	 disorders	 and,	
perhaps,	different	personality	types.	However,	there	should	be	robust	ethical	scrutiny	and	
oversight	 of	 trial	 designs	 that	 expose	 clinical	 trial	 participants,	 who	 by	 definition	 will	 be	
psychiatrically	 unwell,	 to	 the	 emotional	 difficulties	 implicit	 in	 brain	 scanning	 and	 blood	
sampling.	Hitherto,	neuroimaging	studies	using	psychedelics	have	been	restricted	to	healthy	
volunteers.	
	
In	summary,	it	appears	that	a	particularly	careful	and	well-considered	balance	between	the	
needs	 of	 the	 participants	 and	 the	 needs	 of	 the	 trial	 will	 be	 required	 in	 studies	 using	
psychedelics.	Funders	and	research	ethics	committees	will	need	to	understand	the	inherent	
difficulties	 discussed	 above	 if	 they	 are	 to	 scrutinize	 trial	 designs	 using	 psychedelics	
successfully,	 and	 trial	 designers	will	 need,	 similarly,	 to	 be	 detailed	 and	 explicit	 about	 the	
environmental	 and	psychotherapeutic	milieu	 in	which	a	 study	 is	 to	be	performed.	Clinical	
trials	using	psychedelics	will	need	to	be	sufficiently	methodologically	detailed	at	the	point	of	
publication	to	allow	genuine	replication.	Scientific	mechanism	studies	will	need,	ideally,	to	be	
pursued	 alongside	 clinical	 trials	 if	 this	 is	 pragmatic	 and	 ethical.	Within	 this	multi-pronged	
approach	to	evidence	gathering,	and	a	sufficient	degree	of	definition,	replicable	results	and	
common	threads	of	insight	into	the	nature	and	applicability	of	psychedelics	to	medicine	in	
general,	and	to	psychiatry	in	particular,	should	emerge	with	time.	
	
Psilocybin	 was	 marketed	 under	 the	 trade	 name	 ‘Indocybin’	 by	 the	 same	 pharmaceutical	
company	 that	 marketed	 LSD	 (Sandoz).	 Whilst	 it	 was	 used	 in	 individual	 patients,	 this	
systematic	review	did	not	find	any	clinical	trials	of	its	pre-prohibition	use	in	broadly	defined	
mood	disorder.	This	is	likely	to	be	because	psilocybin	(and	its	active	metabolite,	psilocin)	were	
not	isolated	until	1959,	and	the	drug	marketed	after	this(Hofmann	et	al.,	1959).	By	this	time,	
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LSD	research	was	well	underway	and	it	 is	 likely	that	most	clinicians	would	have	wanted	to	
stick	 to	 what	 was	 an	 established	 pharmaceutical	 entity,	 rather	 than	 risk	 the	 potential	
complications	of	trying	a	new	one.	With	this	in	mind,	it	is	notable	that	psilocybin	has	been	
favoured	over	LSD	in	modern	clinical	trials.	There	are	several	possible	reasons	for	this.	Firstly,	
psilocybin	 has	 a	 shorter	 duration	 of	 action	 than	 LSD	or	mescaline,	which	makes	 day-case	
treatment	sessions	feasible,	without	the	need	for	supervised	(and	costly)	overnight	hospital	
stays.	Secondly,	anecdotal	evidence	from	recreational	users	suggests	that	psilocybin	is	 less	
liable	 to	 occasion	 highly	 distressing	 psychological	 reactions	 (although	 this	may	 simply	 be	
because	psilocybin	is	easier	to	measure	than	LSD).	Finally,	and	perhaps	most	importantly,	LSD	
remains	a	particularly	stigmatized	drug.	Not	only	is	this	likely	to	colour	individual	experiences	
of	the	drug	effect,	but	it	is	also	likely	that	this	stigma	still	negatively	affects	the	chances	of	
successful	applications	to	grant	funders	and	research	ethics	committees.	
	
These	observations	lead	naturally	to	a	discussion	about	the	risks	of	using	psychedelic	drugs	in	
medical	 and	 recreational	 settings.	 Physiologically,	 psychedelics	 (particularly	 LSD	 and	
psilocybin)	are	notably	safe.	LSD	and	psilocybin	have	a	toxicity	ratio	(estimated	lethal	dose	as	
a	ratio	of	the	estimated	therapeutic	dose)	of	one	thousand	or	more	(alcohol,	by	comparison,	
has	a	toxicity	ratio	of	about	10,	cocaine	about	15,	ketamine	about	38	and	fluoxetine	about	
100)(Gable,	2004).		
	
The	risk	of	harm	from	recreational	use	of	psychedelics	should	not	be	conflated	with	the	risk	
of	harm	from	medical	use.	Turning	to	recreational	use	first.	In	2010,	an	analysis	of	harms	to	
the	end-user	and	society	caused	by	a	range	of	recreationally	used	psychoactive	substances	
ranked	LSD	and	psilocybin	amongst	the	safest	of	all	those	studied(Nutt	et	al.,	2010),	however	
the	precipitation	of	psychotic	disorders	by	psychedelics	remains	a	concern.		Carhart-Harris	et	
al,	 in	 a	 web-based	 self-report	 questionnaire	 of	 recreational	 use	 of	 psychedelics,	 noted	
prolonged	psychotic	reactions	were	reported	by	1.3%	(six	of	463)	of	LSD	users	and	1.6%	(eight	
of	 503)	 of	 psilocybin	 users	 in	 their	 sample(Carhart-Harris	 and	 Nutt,	 2010).	 Howevr,	 this	
proportion	included	those	reporting	derealisation,	which	is	generally	classified	as	an	anxiety	
derived	phenomenon	rather	than	a	psychotic	phenomenon.	Despite	this,	the	prevalence	is	
not	 significantly	 greater	 than	 might	 be	 expected	 in	 the	 general	 population.	 Three	 large	
population	studies	have	found	that	use	of	psychedelics	is	associated	with	a	lower	relative	risk	
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of	 suicide(Hendricks	 et	 al.,	 2015),	 need	 for	 psychiatric	 medication	 and	 psychological	
distress(Johansen	 and	 Krebs,	 2015),	 and	 recidivism(Hendricks	 et	 al.,	 2014).	 Despite	 the	
authors	 attempting	 to	 correct	 for	 socio-demographic	 variables	 in	 these	 studies,	 it	 is	 still	
possible	that	these	results	are	confounded	by	users	of	psychedelics	tending	not	to	be	from	
such	 socially	 disadvantaged	 groups	when	 compared	 to	 users	 of	 other	 recreationally	 used	
substances.	Very	rare,	reports	of	recreational	users	committing	apparent	acts	of	suicide	whilst	
under	 the	 influence	of	psychedelics	do	exist,	 and	are	unfortunately	emphasized	by	media	
outlets(Keeler	and	Reifler,	1967;	Reynolds	and	Jindrich,	1985).	
	
Turning	 to	 harm	 in	medical	 settings,	 Cohen	noted	 a	 single	 case	 of	 prolonged	 (>48	 hours)	
psychosis	in	a	survey	of	1,200	research	participants	given	psychedelics,	and	this	case	turned	
out	to	have	an	identical	twin	suffering	with	schizophrenia(Cohen,	1960).	Savage	et	al.	in	1973	
noted	that	of	‘the	nearly	500	diverse	patients	treated	[with	LSD]’	only	2	cases	of	psychosis	
were	noted.	This	first	was	in	a	21-year-old	patient	with	‘severe	chronic	neurosis’	treated	with	
350	micrograms	 of	 LSD.	 This	 patient	 had	 a	 history	 of	 psychotic	 episodes	 in	 the	 past,	 and	
recovered	with	psychotherapy	and	antipsychotic	medication.	The	second	case	was	a	‘schizoid	
subject’	 with	 a	 history	 of	 alcoholism,	 but	 no	 further	 details	 were	 given	 about	 the	 case.	
According	 to	 recent	guidelines(M	Johnson	et	al.,	2008),	 the	 first	 two	of	 these	participants	
would	have	been	excluded	from	participation	in	modern	trials,	whilst	it	is	impossible	to	tell	
whether	the	third	would	or	would	not	have.		
	
In	the	most	comprehensive	review	of	specific	adverse	reactions	to	psychedelics	 in	medical	
and	 recreational	 settings,	 Strassman(Strassman,	 1984)	 pointed	 out	 that	 researcher’s	 and	
clinician’s	attitudes	to	psychedelics	appeared	to	result	in	considerable	variation	in	judgement	
about	what	was,	and	was	not,	considered	a	risk	or	an	adverse	event:	
	
“It	 is	 important	 to	 use	 caution	 in	 discussing	 the	 concept	 of	 adverse	 reactions	 to	
psychedelic	drugs.	At	one	extreme	are	those	who	believe	that	the	drug-induced	state	
itself	is	either	primarily	a	pathological	one,	i.e.	a	"model	psychosis",	or	that	the	desire	
to	induce	such	a	state	is	a	function	of	pre-existing	personality	dysfunction.	At	the	other	
extreme	is	the	view	that	even	the	most	disorganized,	frightened,	dysfunctional,	and	
regressed	 reactions	 to	 psychedelic	 drugs	 are	 necessary/healthy	 reactions	 seen	 in	
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throwing	 off	 "straight"	 society’s	 "shackles"	 and	 in	 reaching	 a	 "higher"	 level	 of	
consciousness.	The	description	and/or	reporting	of	adverse	reactions	to	psychedelics	
is,	therefore,	subject	to	some	degree	of	investigators’	perspective	on	the	use	of	these	
drugs.”	
	
As	a	natural	extension	of	this,	Strassman	also	points	out,	about	LSD:	
	
“One	of	the	most	confounding	aspects	of	almost	all	studies	of	either	acute	or	chronic	
effects	 of	 LSD	 is	 their	 lack	 of	 pre-LSD	 data.	 The	 role	 of	 LSD	 in	 producing	 "LSD	
psychoses,"	brain	damage,	long-lasting	personality	change,	and	flashbacks	is	difficult,	
if	not	impossible	to	discern	without	pre-LSD	values	for	the	dependent	variables”	
	
His	conclusions	about	the	adverse	effects	of	LSD	are	summed	up	in	the	following	paragraph:	
	
“With	 the	 available	 data,	 it	 appears	 that	 the	 incidence	 of	 adverse	 reactions	 to	
psychedelic	drugs	is	 low	when	individuals,	both	normal	volunteers	and	patients,	are	
carefully	 screened	 and	 prepared,	 supervised	 and	 followed	 up,	 and	 given	 judicious	
doses	 of	 pharmaceutical	 quality	 drug.	 The	 few	 prospective	 studies	 noting	 adverse	
reactions	have	fairly	consistently	described	characteristics	predicting	poor	response	to	
these	drugs.	The	majority	of	studies	of	adverse	reactions,	retrospective	in	nature,	have	
described	a	constellation	of	premorbid	characteristics	in	individuals	seeking	treatment	
for	 these	 reactions	 where	 drugs	 of	 unknown	 purity	 were	 taken	 in	 unsupervised	
settings.”	
	
Whilst	 such	 research	 certainly	 deserves	 repetition	 (particularly	 because	modern	 research	
with	psychedelics	is	tending	to	use	psilocybin)	a	summation	of	the	evidence	suggests	that	the	
risks	associated	with	medically	controlled	and	supervised	use	of	psychedelics	are	low	and	that	
evidence-based	 guidelines(M	 Johnson	 et	 al.,	 2008)	 improve	 safety	 even	 further.	 In	 this	
context	it	is	also	notable	that	far	more	dangerous	substances,	such	as	opiates,	are	routinely	
used	in	medical	therapy	even	though	recreational	use	is	also	widespread,	and	certainly	much	
more	dangerous	than	recreational	use	of	psychedelics.	No	deaths	have	been	unambiguously	
linked	to	the	physiological	toxicity	of	classical	serotonergic	psychedelics	whereas	in	2014,	in	
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the	 US	 alone,	 10,574	 people	 died	 of	 street	 heroin	 overdoses,	 and	 a	 further	 18,893	 from	
prescription	opiate	overdoses(National	Center	for	Health	Statistics,	2015).		
	
A	single	pilot	study	of	psilocybin	in	the	treatment	of	resistant	major	depressive	disorder	was	
recently	 completed	 in	 the	United	Kingdom(Carhart-Harris,	 Bolstridge,	 et	 al.,	 2016).	 In	 this	
open-label	 feasibility	 trial,	 12	patients	with	 treatment-resistant	unipolar	major	depression	
received	two	oral	doses	of	psilocybin	(10	mg	and	25	mg)	1	week	apart,	in	a	supportive	setting,	
with	psychological	 support	and	medical	 supervision	before,	during	and	after	each	session.	
Follow	up	was	from	1	week	to	3	months	post	treatment.	8	of	12	patients	achieved	complete	
remission	 of	 symptoms	 at	 1	 week	 and	 7	 patients	 (58%)	 continued	 to	 meet	 criteria	 for	
response	(50%	reduction	in	BDI	score	relative	to	baseline)	at	3	months,	with	5	of	these	still	in	
complete	remission.	The	therapy	was	well	tolerated,	with	no	serious	adverse	events.	
	
The	 American	 psychologist	 and	 LSD	 researcher,	 Betty	 Eisner,	 summarised	 the	
psychotherapeutic	mechanism	 by	which	 LSD,	 and	 by	 implication	 other	 psychedelics,	may	
work	as	follows(Eisner	and	Cohen,	1958):	
1) LSD	lessens	defensiveness	
2) There	is	a	heightened	capacity	to	relive	early	experiences	with	accompanying	release	
of	feelings	
3) Therapist-patient	relationships	are	enhanced	
4) There	is	an	increased	appearance	of	unconscious	material.	
If	the	aetiology	of	UMD	in	some	patients	can	be	understood,	at	least	in	part,	as	the	present	
day	emotional	and	behavioural	sequelae	of	unresolved	traumas	and	emotional	conflicts	from	
the	past,	with	anxieties	about	 the	 future,	 it	 is	 reasonable	 to	hypothesize	 that	psychedelic	
psychotherapy	will	catalyse	the	resolution	of	such	conflicts	in	a	proportion	of	patients	where	
other	treatment	modalities	have	failed.		
	
There	is	a	pressing	economic	need	for	such	interventions.	Unipolar	depressive	disorder	costs	
the	 United	 States	 alone	 over	 $210	 billion	 annually(Greenberg	 et	 al.,	 2015).	 Response	 to	
treatment	is	often	suboptimal	and	entrenched,	maladaptive	patterns	of	thought,	feeling	and	
behaviour	are	the	hallmark	of	resistance	to	treatment.	Whilst	long,	detailed	forms	of	dynamic,	
analytical	and	behavioural	psychotherapy	may	change	such	patterns	over	the	course	of	years,	
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they	 are	 expensive	 and	 time	 consuming.	 Psychedelic	 therapy	 may	 represent	 a	 form	 of	
catalysed	 psychotherapy	 whereby	 the	 drug	 acts	 to	 hasten	 the	 breakdown	 of	 habitual	
maladaptive	 templates	of	 thinking	and	behaviour	 in	supportive	 therapeutic	environments.	
The	evidence	from	the	pre-prohibition	literature,	whilst	unsystematic	and	methodologically	
suboptimal,	suggests	that	this	is	worth	re-investigating.	Furthermore,	a	recent	pilot	study	in	
treatment	resistant	depressive	disorder	has	shown	encouraging	results.	Taken	together,	the	
evidence	 suggests	 that	 there	 is	 a	 strong	medical	 and	 economic	 argument	 for	 the	 further	
investigation	 of	 psychedelics	 in	 the	 treatment	 of	 unipolar	 mood	 disorders	 in	 sensitively	
designed,	modern	clinical	trials.	
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